Repare Therapeutics (RPTX) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Repare Therapeutics in October 2026.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics (RPTX) Stock Forecast
Analyst price target, next 12 months
$12.00
+1021.5% vs today's $1.07
Price range over the last 12 months
Close to its 12-month low
Analysts covering Repare Therapeutics have a consensus 12-month target of $12.00, above the current price of $1.07.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Mar 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Repare Therapeutics' stock with a target price of $9.6, indicating strong potential growth.
Financial Health
Repare Therapeutics is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
